Editorials

Regulating the pharmaceutical industry

BMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7102.200 (Published 26 July 1997) Cite this as: BMJ 1997;315:200

Pricing should be renegotiated to control research costs and encourage cost effectiveness

  1. Alan Maynard, Professor of economicsa,
  2. Karen Bloor, Research fellow in health economicsb
  1. a York Health Economics Consortium, University of York, York YO1 5DD
  2. b Department of Health Sciences and Clinical Evaluation, University of York, York YO1 5DD

    The pharmaceutical price regulation scheme1 is a voluntary agreement between Britain's Department of Health and the Association of the British Pharmaceutical Industry in which companies negotiate generous target profit rates from sales of drugs to the NHS (17-21% rate of return on investment in research and development). The scheme's objectives are to secure the provision of safe and effective medicines to the NHS at reasonable prices; to promote a strong pharmaceutical industry in Britain; and to encourage the efficient and competitive development and supply of medicines worldwide.1 The scheme was renewed in 1993 for five years and is currently under review. Although the scheme has been successful in helping to maintain the British pharmaceutical industry, its objectives conflict, and the way the scheme operates pays little regard to other health policy objectives. As the price of renegotiation, the government should request changes to the scheme, to minimise the inherent conflicts and to ensure that the scheme supports other policies.

    There is considerable evidence of the scheme's success at achieving a strong industry.2 However, drug prices in Britain are …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe